| Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges RM Shallis, R Wang, A Davidoff, X Ma, AM Zeidan Blood reviews 36, 70-87, 2019 | 770 | 2019 |
| Luspatercept in patients with lower-risk myelodysplastic syndromes P Fenaux, U Platzbecker, GJ Mufti, G Garcia-Manero, R Buckstein, ... New England Journal of Medicine 382 (2), 140-151, 2020 | 472 | 2020 |
| Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study A Sharma, NS Bhatt, A St Martin, MB Abid, J Bloomquist, RF Chemaly, ... The Lancet Haematology 8 (3), e185-e193, 2021 | 350 | 2021 |
| Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology PL Greenberg, RM Stone, A Al-Kali, SK Barta, R Bejar, JM Bennett, ... Journal of the National Comprehensive Cancer Network 15 (1), 60-87, 2017 | 326 | 2017 |
| Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies C Liao, D Zhang, C Mungo, DA Tompkins, AM Zeidan Gynecologic oncology 135 (1), 163-171, 2014 | 175 | 2014 |
| Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it AM Zeidan, RM Shallis, R Wang, A Davidoff, X Ma Blood reviews 34, 1-15, 2019 | 163 | 2019 |
| Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia CD DiNardo, AS Stein, EM Stein, AT Fathi, O Frankfurt, AC Schuh, ... Journal of Clinical Oncology 39 (1), 57-65, 2021 | 143 | 2021 |
| Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort M Stahl, M DeVeaux, P Montesinos, R Itzykson, EK Ritchie, MA Sekeres, ... Blood advances 2 (8), 923-932, 2018 | 132 | 2018 |
| HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation AM Zeidan, PM Forde, H Symons, A Chen, BD Smith, K Pratz, H Carraway, ... Biology of Blood and Marrow Transplantation 20 (3), 314-318, 2014 | 127 | 2014 |
| The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort M Stahl, M DeVeaux, T De Witte, J Neukirchen, MA Sekeres, AM Brunner, ... Blood advances 2 (14), 1765-1772, 2018 | 124 | 2018 |
| Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and … CD DiNardo, AC Schuh, EM Stein, P Montesinos, AH Wei, S de Botton, ... The Lancet Oncology 22 (11), 1597-1608, 2021 | 119 | 2021 |
| Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era? Y Liu, JP Bewersdorf, M Stahl, AM Zeidan Blood reviews 34, 67-83, 2019 | 114 | 2019 |
| Impact of a venous thromboembolism prophylaxis “smart order set”: improved compliance, fewer events AM Zeidan, MB Streiff, BD Lau, SR Ahmed, PS Kraus, DB Hobson, ... American journal of hematology 88 (7), 545-549, 2013 | 109 | 2013 |
| Eliminating health care disparities with mandatory clinical decision support: the venous thromboembolism (VTE) example BD Lau, AH Haider, MB Streiff, CU Lehmann, PS Kraus, DB Hobson, ... Medical care 53 (1), 18-24, 2015 | 107 | 2015 |
| Current therapy of myelodysplastic syndromes AM Zeidan, Y Linhares, SD Gore Blood Reviews 27 (5), 243-259, 2013 | 104 | 2013 |
| Selecting initial treatment of acute myeloid leukaemia in older adults NA Podoltsev, M Stahl, AM Zeidan, SD Gore Blood reviews 31 (2), 43-62, 2017 | 102 | 2017 |
| Epigenetic therapy combinations in acute myeloid leukemia: what are the options? JP Bewersdorf, R Shallis, M Stahl, AM Zeidan Therapeutic advances in hematology 10, 2040620718816698, 2019 | 96 | 2019 |
| Aplastic anemia: Etiology, molecular pathogenesis, and emerging concepts RM Shallis, R Ahmad, AM Zeidan European journal of haematology 101 (6), 711-720, 2018 | 94 | 2018 |
| Pegasparaginase: where do we stand? A Zeidan, ES Wang, M Wetzler Expert opinion on biological therapy 9 (1), 111-119, 2009 | 94 | 2009 |
| Epigenetics in cancer: a hematological perspective M Stahl, N Kohrman, SD Gore, TK Kim, AM Zeidan, T Prebet PLoS genetics 12 (10), e1006193, 2016 | 93 | 2016 |
Guillermo Garcia-ManeroMD Anderson Cancer Center在 mdanderson.org 的电子邮件经过验证
